Summit Therapeutics Inc. Annual Operating Income (Loss) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Summit Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
  • Summit Therapeutics Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$59.6M, a 277% decline year-over-year.
  • Summit Therapeutics Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$159M, a 73.1% increase year-over-year.
  • Summit Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$610M, a 746% decline from 2022.
  • Summit Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$72.1M, a 16.4% increase from 2021.
  • Summit Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$86.2M, a 62% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$610M -$538M -746% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 -$72.1M +$14.1M +16.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 -$86.2M -$33M -62% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$53.2M -$25.7M -93.6% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
2019 -$27.5M -$32.9M -610% Feb 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 $5.39M +$33.8M Feb 1, 2018 Jan 31, 2019 10-K 2021-03-31
2017 -$28.4M Feb 1, 2017 Jan 31, 2018 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.